TherapeuticsMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net loss was USD 9.4 million compared to net income of USD 34.3 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 5.34 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 5.34 a year ago. Basic loss per share was USD 0.92 compared to basic earnings per share of USD 3.86 a year ago. Diluted loss per share was USD 0.92 compared to diluted earnings per share of USD 3.86 a year ago.